SHANGHAI, June 29, 2018 /PRNewswire/ -- I-Mab Biopharma, a company focusing on innovative Biologics in therapeutic areas of immuno-oncology and immuno-inflammation, announced the completion of Series C financing for USD
Growth Capitalist (https://growthcapitalist.com/2018/06/i-mab-successfully-raised-usd-220-million-in-series-c-funding/)
SHANGHAI, June 29, 2018 /PRNewswire/ -- I-Mab Biopharma, a company focusing on innovative Biologics in therapeutic areas of immuno-oncology and immuno-inflammation, announced the completion of Series C financing for USD